Advertisement

Advertisement

SCYX Stock Latest News

SCYNEXIS Director Steven Gilman Announces Board Retirement

Company AnnouncementsSCYNEXIS Director Steven Gilman Announces Board Retirement

Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target

PremiumRatings

Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target

15d ago

SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease

PremiumCompany Announcements

SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease

1M ago

SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline

PremiumCompany Announcements

SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline

1M ago

SCYNEXIS Raises $40 Million in Strategic Private Placement

PremiumCompany Announcements

SCYNEXIS Raises $40 Million in Strategic Private Placement

1M ago

Poxel announces sale of PXL770 to Scynexis for up to $196M

PremiumThe FlyPoxel announces sale of PXL770 to Scynexis for up to $196M

1M ago

Scynexis completes acquisition of PXL-770 for treatment of kidney disease

The Fly

Scynexis completes acquisition of PXL-770 for treatment of kidney disease

1M ago

Scynexis announces $40M private placement

The Fly

Scynexis announces $40M private placement

1M ago

Buy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity

PremiumRatings

Buy Rating on Scynexis Backed by Strong Cash Runway and Differentiated Next‑Generation Antifungal SCY‑247 Opportunity

1M ago

Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247

PremiumThe Fly

Scynexis announces first patients dosed in Phase 1 SAD, MAD trial of SCY-247

2M ago

Cero Therapeutics appoints Eric Francois to board of directors

PremiumThe Fly

Cero Therapeutics appoints Eric Francois to board of directors

2M ago

Scynexis announces presentation highlighting data from SCY-247

PremiumThe Fly

Scynexis announces presentation highlighting data from SCY-247

3M ago

Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247

PremiumThe FlyScynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247

3M ago

Scynexis granted 180-day extension by Nasdaq to regain compliance

The Fly

Scynexis granted 180-day extension by Nasdaq to regain compliance

4M ago

SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path

Company Announcements

SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path

4M ago

Scynexis completes transfer of BREXAFEMME NDA to GSK

PremiumThe Fly

Scynexis completes transfer of BREXAFEMME NDA to GSK

5M ago

Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration

PremiumThe Fly

Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration

5M ago

SCYNEXIS: Strong Financial Position and Promising Antifungal Pipeline Drive Buy Rating

PremiumRatings

SCYNEXIS: Strong Financial Position and Promising Antifungal Pipeline Drive Buy Rating

6M ago

SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates

PremiumCompany Announcements

SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates

6M ago

Scynexis reports Q3 EPS (17c), consensus (20c)

PremiumThe FlyScynexis reports Q3 EPS (17c), consensus (20c)

6M ago

SCYX Upcoming Earnings Report: What to Expect?

Pre-Earnings

SCYX Upcoming Earnings Report: What to Expect?

6M ago

Scynexis price target lowered to $3 from $4 at Guggenheim

The Fly

Scynexis price target lowered to $3 from $4 at Guggenheim

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >